Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report

Authors

  • Abdul Rafeh Naqash Division of Hematology/Oncology, East Carolina University, Greenville, NC, USA
  • Li V. Yang Division of Hematology/Oncology, East Carolina University, Greenville, NC, USA
  • Edward J. Sanderlin Division of Hematology/Oncology, East Carolina University, Greenville, NC, USA
  • Druid C. Atwell Division of Hematology/Oncology, East Carolina University, Greenville, NC, USA
  • Paul R. Walker Thoracic Oncology, East Carolina University, Greenville, NC, USA

DOI:

https://doi.org/10.1080/0284186X.2017.1406668

Abstract

No Abstract Available

Downloads

Download data is not yet available.

Downloads

Published

2018-05-04

How to Cite

Rafeh Naqash, A. ., Yang, L. V. ., Sanderlin, E. J. ., Atwell, D. C. ., & Walker, P. R. . (2018). Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncologica, 57(5), 705–708. https://doi.org/10.1080/0284186X.2017.1406668